EUROBIO-SCIENTIFIC: directors' dealings · France · AMF

About EUROBIO-SCIENTIFIC

Eurobio Scientific is a French specialist in in vitro diagnostics and life sciences, listed on Euronext Growth Paris under the ticker ALERS and ISIN FR0013240934. The group operates as an integrated specialty diagnostics player, focused on the research, development, manufacturing and commercialization of tests and reagents used by laboratories, hospitals and research centers. Its portfolio is centered on three core clinical areas: infectious diseases, transplantation and oncology, alongside life-science research tools and quality-control solutions. The company’s development has been shaped by a series of strategic acquisitions and integrations. Eurobio Scientific was formed after Exonhit acquired Ingen in 2012 and later Eurobio in 2017, creating a broader platform in specialty diagnostics. Over time, the group has built recognized expertise in niche segments such as molecular biology, transplant diagnostics and laboratory quality control, combining proprietary products with exclusive distribution agreements for third-party technologies. From a product standpoint, Eurobio Scientific offers a diversified range of diagnostic and research solutions. Its portfolio includes molecular biology assays, infectious-disease test panels, autoimmunity solutions, culture media, and products for corneal graft transport and preservation. The company also distributes instruments and reagents for life-science research laboratories. This mix of proprietary and distributed products is an important competitive strength, supporting both differentiation and recurring revenues. Eurobio Scientific positions itself as a leading player in the French specialty IVD market, while maintaining a meaningful international footprint. The group is headquartered in the Paris region and has subsidiaries or affiliates in the United States, notably in San Diego and Chicago, as well as across several European countries including the UK, Germany, Switzerland, Belgium, the Netherlands and Italy. In 2024, international markets accounted for 41% of group revenue, confirming the company’s growing geographic diversification. Financially, 2024 highlighted the resilience of the core business, with revenue rising to €154.2 million, up 19%, and positive cash generation. Eurobio Scientific has also continued to execute a growth-by-acquisition strategy, including the EndoPredict oncology test and recent initiatives aimed at strengthening its transplantation franchise. Overall, the group’s strategic direction is clear: to build a larger, more proprietary and more international specialty diagnostics platform with a stronger position in high-value clinical niches.